Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Genfit clinical trials
The registry lists 23 studies whose lead sponsor is Genfit. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 23, 2026.
Keep track of what changes. Save the Genfit studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Genfit.
- Genfit23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruitingNCT05874414Phase 1/2
- Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver FailureNot yet recruitingNCT07694297Phase 2
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®TerminatedNCT05900050Phase 2
- Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy VolunteersCompletedNCT07110441Phase 1
- A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic EncephalopathyTerminatedNCT06987968Phase 2
- Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT01694849Phase 2
- Nitazoxanide Pharmacokinetic Parameters in Renal Impaired SubjectsCompletedNCT05368935Phase 1
- Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired PatientsCompletedNCT05116826Phase 1
- Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT02704403Phase 3
- Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)TerminatedNCT03883607Phase 2
- Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)TerminatedNCT03953456Phase 2
- Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and IndomethacinCompletedNCT03985969Phase 1
- Elafibranor Pharmacokinetic Parameters in Renal Impaired PatientsCompletedNCT03844555Phase 1
- Elafibranor Pharmacokinetic Parameters in Elderly Healthy VolunteersCompletedNCT04171752Phase 1
- Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic AcidCompletedNCT03124108Phase 2
- Elafibranor Pharmacokinetic Parameters in Hepatic Impaired PatientsCompletedNCT03765671Phase 1
- Mass Balance Study of 14C-labelled GFT505 in Healthy VolunteersCompletedNCT02142127Phase 1
- Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy VolunteersCompletedNCT02091310Phase 1
- Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505CompletedNCT01474161Phase 1
- Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal ObesityCompletedNCT01271777Phase 2
- Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes MellitusCompletedNCT01261494Phase 2
- Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.CompletedNCT01275469Phase 2
- Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal ObesityCompletedNCT01271751Phase 2